Form D · Pharmaceuticals
Brickell Biotech, Inc.
Boulder, CO · CIK 0000819050
Offering snapshot reported Jun 7, 2022 · SEC filing
- Reported sold
- $10 Offering amount: $10
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $10 Reported outside-investor minimum
- First sale
- May 25, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 7, 2022 | Initial | $10 | No comparison | 1 | SEC filing |
| Jun 25, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-448413
Source: Form D, filed Jun 7, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jose Augusto Breton | Executive |
| Robert Busard Brown | Director, Executive |
| Deepak Chadha | Executive |
| Reginald Lee Hardy | Director |
| Monica Elisabeth Luchi | Executive |
| Gary Alan Lyons | Director |
| Albert Nicolas Marchio | Executive |
| David Robert Mc Avoy | Executive |
| Vijay Bal Samant | Director |
| Andrew David Sklawer | Executive |
| Dennison Theodore Veru | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
5777 Central Avenue Suite 102
Boulder, CO, 80301
Boulder, CO, 80301